Effects of L-carnitine and Ginkgo biloba extract (EGb 761) in experimental bleomycin-induced lung fibrosis

Pharmacological Research

Volumn 45, Issue 6, 2002, Pages 461-467

  Daba, Mohamed H ^a   Abdel Aziz, Abdel Aziz H ^a   Moustafa, Adel M ^a   Al Majed, Abdulhakeem A ^a   Al Shabanah, Othman A ^a   El Kashef, Hassan A ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Bleomycin; Ginkgo biloba; L carnitine; Lung fibrosis; TNF

Indexed keywords

BLEOMYCIN; CARNITINE; DRINKING WATER; GINKGO BILOBA EXTRACT; LIPID PEROXIDE; SEROTONIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; LUNG FIBROSIS; LUNG HOMOGENATE; LUNG PARENCHYMA; LUNG TOXICITY; MEASUREMENT; NONHUMAN; PRIORITY JOURNAL; PULMONARY ARTERY; RAT;

EID: 0036418572     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.2002.0985     Document Type: Article

References (51)

1. Suntres ZE, Shek PN. Protective effect of liposomal alpha-tocopherol against bleomycin-induced lung injury. Biomed Environ Sci 1997; 10: 47-59.
2. Chandler DB. Possible mechanisms of bleomycin-induced fibrosis. Clin Chest Med 1990; 11: 21-30.
3. Keane MP, Belperio JA, Arenberg DA, Burdick MD, Xu ZJ, Xue YY, Strieter RM. IFN-gamma-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis. J Immunol 1999; 163: 5686-92.
4. Smith RE, Strieter RM, Phan SH, Kunkel SL. C-C chemokines: Novel mediators of profibrotic inflammatory response to bleomycin challenge. Am J Respir Cell Mol Biol 1996; 15: 693-702.
5. Ortiz LA, Lasky J, Hamilton RF Jr, Holian A, Hoyle GW, Banks W, Peschon JJ, Brody AR, Lungarella G, Friedman M. Expression of TNF and the necessity of TNF receptors in bleomycin-induced lung injury in mice. Exp Lung Res 1998; 24: 721-43.
6. Habib MP, Lackey DL, Lantz RC, Sobonya RE, Grad R, Earnest DL, Bloom JW. Vitamin A pretreatment and bleomycin-induced rat lung injury. Res Commun Chem Pathol Pharmacol 1993; 81: 199-208.
7. Karam H, Hurbain-Kosmath I, Housset B. Antioxidant activity in alveolar epithelial type 2 cells of rats during the development of bleomycin injury. Cell Biol Toxicol 1998; 14: 13-22.
8. Parizada B, Werber MM, Nimrod A. Protective effects of human recombinant MnSOD in adjuvant arthritis and bleomycin-induced lung fibrosis. Free Radic Res Commun 1991; 15: 297-301.
9. Khalil N, Whitman C, Zuo L, Danielpour D, Greenberg A. Regulation of alveolar macrophage transforming growth factor-beta secretion by corticosteroids in bleomycin-induced pulmonary inflammation in the rat. J Clin Invest 1993; 92: 1812-18.
10. O'Neil CA, Giri SN. Biochemical mechanisms for the attenuation of bleomycin-induced lung fibrosis by treatment with niacin in hamsters: the role of NAD and ATP. Exp Lung Res 1994; 20: 41-56.
11. Evans TW, McAnulty RJ, Rogers DF, Chung KF, Barnes PJ, Laurent GJ. Bleomycin-induced lung injury in the rat: Effects of the platelet-activating factor (PAF) receptor antagonist BN52021 and platelet depletion. Environ Health Perspect 1990; 85: 65-9.
12. Giri SN, Sharma AK, Hyde DM, Wild JS. Amelioration of bleomycin-induced lung fibrosis by treatment with the platelet activating factor receptor antagonist WEB 2086 in hamsters. Exp Lung Res 1995; 21: 287-307.
13. Goa KL, Brogden RN. L-carnitine. Drugs 1987; 34: 1-24.
14. Kobayashi A, Fujisawa S. Effect of L-carnitine on mitochondrial acylCoA esters in the ischemic dog heart. J Mol Cell Cardiol 1994; 26: 499-508.
15. Uziel G, Garavaglia B, Di Donato S. Carnitine stimulation of pyruvate dehydrogenase complex (PDHC) in isolated human skeletal muscle mitochondria. Muscle Nerve 1988; 11: 720-724.
16. Fujisawa S, Kobayasi A, Hironaka Y, Yamazaki N. Effect of L-carnitine on the cellular distribution of carnitine and its acyl derivatives in the ischemic heart. Jpn Heart J 1992; 33: 693-705.
17. Sayed-Ahmed MM, Shaarawy S, Shouman SA, Osman AM. Reversal of doxorubicin-induced cardiac metabolic damage by L-carnitine. Pharmacol Res 1999; 39: 289-96.
18. Sayed-Ahmed MM, Shouman SA, Rezk BM, Khalifa MH, Osman AM, Elmerzabani MM. Propionyl-L-carnitine as potential protective agent against adriamycin-induced impairment of fatty acid beta - Oxidation in isolated heart mitochondria. Pharmacol Res 2000; 41: 143-50.
19. Clostre F. Ginkgo biloba extract (EGb 761). State of knowledge in the dawn of the year 2000. Ann Pharm Fr 1999; 57 (Suppl. 1): 1S8-88.
20. Kleijnen J, Knipschild P. Ginkgo biloba (Tebonina). Lancet 1992; 340: 1136-9.
21. Akisu M, Kultursay N, Coker I, Huseyinov A. Platelet activating factor is an important mediator in hypoxic ischemic brain injury in the newborn rat. Flunarizine and Ginkgo biloba extract reduce PAF concentration in the brain. Biol Neonate 1998; 74: 439-44.
22. DeFeudis FV. In vitro studies with EGb 761. In: Ginkgo Biloba Extract (EGb 761): Pharmacological Activities and Clinical Applications. Paris: Editions Scientifiques Elsevier, 1991: 25-60.
23. Pietri S, Seguin JR, D'Arbigny P, Drieu K, Culcasi M. Ginkgo biloba extract (EGb 761) pretreatment limits free radical-induced oxidative stress in patients undergoing coronary bypass surgery. Cardiovasc Drugs Ther 1997; 11: 121-31.
24. Pincemail J, Dupuis M, Nasr C, Hans P, Haag-Berrurier M, Anton R, Deby C. Superoxide anion scavenging effect and superoxide dismutase activity of Ginkgo biloba extract. Experientia 1989; 45: 708-12.
25. Blom-Muilwijk MC, Vriesendorp R, Veninga TS, Hofstra W, Sleyfer DT, Wieringa RA, Konings AW. Pulmonary toxicity after treatment with bleomycin alone or in combination with hyperoxia. Studies in the rat. Br J Anaesth 1988; 60: 91-97.
26. Fukaya H, Kanno H. Experimental studies of the protective effect of Ginkgo biloba extract (GBE) on cisplatin-induced toxicity in rats. Nippon Jibiinkoka Gakkai Kaiho 1999; 102: 907-17.
27. Abdel-aleem S, El-Merzabani MM, Sayed-Ahmed M, Taylor DA, Lowe JE. Acute and chronic effects of adriamycin on fatty acid oxidation in isolated cardiac myocytes. J Mol Cell Cardiol 1997; 29: 789-97.
28. El-Kashef HA. Hyperglycaemia increased the responsiveness of isolated rabbit's pulmonary arterial rings to serotonin. Pharmacology 1996; 53: 151-9.
29. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95: 351-8.
30. Woessner JF. The determination of hydroxyproline in tissue and protein samples containing small proportions of this amino acid. Arch Biochem Biophys 1961; 93: 440-7.
31. Kelley J. Cytokines of the lung. Am Rev Respir Dis 1990; 141: 765-88.
32. Piguet PF, Collart MA, Grau GE, Kapanci Y, Vassalli P. Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J Exp Med 1989; 170: 655-63.
33. Phan SH, Kunkel SL. Lung cytokine production in bleomycin-induced pulmonary fibrosis. Exp Lung Res 1992; 18: 29-43.
34. Mutsaers SE, Marshall RP, Goldsack NR, Laurent GJ, McAnulty RJ. Effect of endothelin receptor antagonists (BQ-485, R0 47-0203) on collagen deposition during the development of bleomycin-induced pulmonary fibrosis in rats. Pulm Pharmacol Ther 1998; 11: 221-5.
35. Cross CE, Warren D, Gerriets JE, Wilson DW, Halliwell B, Last JA. Deferoxamine injection does not affect bleomycin-induced lung fibrosis in rats. J Lab Clin Med 1985; 106: 433-8.
36. Muraoka Y, Takita T, Umezawa H. In: Cancer chemotherapy, vol. 8. Pinedo HM, Chabner BA, eds. New York: Elsevier, 1986: 65-72.
37. Filderman AE, Genovese LA, Lazo JS. Alterations in pulmonary protective enzymes following systemic bleomycin treatment in mice. Biochem Pharmacol 1988; 37: 1111-6.
38. Giri SN, Chen ZL, Younker WR, Schiedt MJ. Effects of intra-tracheal administration of bleomycin on GSH-shuttle enzymes, catalase, lipid peroxidation and collagen content in the lungs of hamsters. Toxicol Appl Pharmacol 1983; 71: 132-41.
39. Halliwell B. Free radicals, antioxidants, and human disease: Curiosity, cause, or consequence? Lancet 1994; 344: 721-4.
40. Barnes PJ, Karin M. Nuclear factor-kB: A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066-71.
41. Shenkar R, Abraham E. Hemorrahage induced rapid in vivo activation of CREB and NF-kB in murine intraparenchymal lung mononuclear cells. Am J Respir Cell Mol Biol 1997; 16: 145-52.
42. Gossart SC, Cambon C, Orfila MH, Seguelas JC, Lepert J, Rami P, Carre P, Pipy B. Reactive oxygen intermediates as regulators of TNF-α production in rat lung inflammation induced by silica. J Immunol 1996; 156: 1540-8.
43. El-Kashef HA, Hofman WF, Ehrhart IC. Effect of lipoxygenase inhibitor on vasoconstriction in dog lung. Am J Physiol 1990; 257: H1977-82.
44. Hofman WF, Ehrhart IC. Vascular reactivity and permeability to serotonin in cyclooxygenase inhibited dog lung. Am J Physiol 1988; 255: H1096-105.
45. Hofman WF, Jackson WF, El-Kashef HA, Ehrhart IC. Modulation of vascular reactivity to serotonin in the dog lung. J Appl Physiol 1991; 71: 217-22.
46. Sjogren A, Edvinsson L. Vasomotor changes in isolated coronary arteries from diabetic rats. Acta Physiol Scand 1988; 134: 429-36.
47. Block ER. Factors affecting the fluidity of the endothelial cell plasma membrane. In: Vascular Endothelium: Receptors and Transduction Mechanisms. Catravas JD, Norman Gillis C, Ryan US, eds. New York: Plenum Press, 1989: 29-42.
48. Orr FW, Adamson IY, Warner D, Leroyer V, Werner L, Shaughnessy S, Young L. The effects of oxygen radical-mediated pulmonary endothelial damage on cancer metastasis. Mol Cell Biochem 1988; 84: 189-98.
49. Du G, Willet K, Mouithys-Mickalad A, Sluse-Goffart CM, Droy-Lefaix MT, Sluse FE. EGb 761 protects liver mitochondria against injury induced by in vitro anoxia/reoxygenation. Free Radic Biol Med 1999; 27: 596-604.
50. El-Khatib AS, Moustafa AM, Abdel-Aziz AH, Al-Shabanah OA, El Kashef HA. Ginkgo biloba extract (EGb 761) modulates bleomycin-induced acute lung injury in rats. Tumori 2001; 87: 417-22.
51. Agha AM, El-Fattah AAA, El-Zuhair HH, Al-Rikabi AC. Chemo-preventive effect of Ginkgo biloba extract against benzo(a)pyrene-induced forestomach carcinogenesis in mice: Amelioration of doxorubicin cardiotoxicity. J Exp Clin Cancer Res 2001; 20: 39-50.